The non-surgical Stretta® procedure employing low power and low temperature radiofrequency (RF) energy is effective in control of gastroesophageal reflux disease (GERD), and eliminates or reduces the need for medication 10...
The non-surgical Stretta® procedure employing low power and low temperature radiofrequency (RF) energy is effective in control of gastroesophageal reflux disease (GERD), and eliminates or reduces the need for medication 10...
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11...
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11...
Sony Biotechnology Inc. ("Sony") today announced the launch of the new SH800 Cell Sorter 8-well strip holder and 130um sorting chip. Sony will also be exhibiting its newly rebranded reagent portfolio. New data collected on...
Sony Biotechnology Inc. ("Sony") today announced the launch of the new SH800 Cell Sorter 8-well strip holder and 130um sorting chip. Sony will also be exhibiting its newly rebranded reagent portfolio. New data collected on...
Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that...
Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that...
New interactive learning forums will be held by the most innovative thought leaders of the medical device industry at the 2013 Medical Device & Manufacturing East conference and expo, from June 18-20 in Philadelphia. ...
New interactive learning forums will be held by the most innovative thought leaders of the medical device industry at the 2013 Medical Device & Manufacturing East conference and expo, from June 18-20 in Philadelphia. ...
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved 50% enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical...
Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved 50% enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical...
Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013 WCIO Program Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University...
Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013 WCIO Program Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University...
Yongye International, Inc. (NASDAQ: YONG) ("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China, today announced that, on May 16,...
Yongye International, Inc. (NASDAQ: YONG) ("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China, today announced that, on May 16,...
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's...
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's...
Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001...
Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001...
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2013, before market on Tuesday, May 28,...
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2013, before market on Tuesday, May 28,...
Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in...
Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in...
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1...
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1...
PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock....
PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock....
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on...
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on...
-Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard™ Embolic Protection Stent- - Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data - InspireMD, Inc....
-Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard™ Embolic Protection Stent- - Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data - InspireMD, Inc....
Amgen (NASDAQ:AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square in New York City, beginning at 10:00 a.m. Eastern Daylight Time. Joseph P....
Amgen (NASDAQ:AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square in New York City, beginning at 10:00 a.m. Eastern Daylight Time. Joseph P....
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced...
HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced...
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that...
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that...
Valtech Cardio Ltd., a medical device company that develops solutions for mitral valve repair and replacement, announced today that two patients diagnosed with severe mitral regurgitation (MR) have been treated successfully...
Valtech Cardio Ltd., a medical device company that develops solutions for mitral valve repair and replacement, announced today that two patients diagnosed with severe mitral regurgitation (MR) have been treated successfully...
JETREA® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million Phase IIa study evaluating JETREA® in wet AMD patients shows 24% VMA resolution rate for JETREA® treated...
JETREA® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million Phase IIa study evaluating JETREA® in wet AMD patients shows 24% VMA resolution rate for JETREA® treated...
BioTrinity 2013 the Most Successful Yet: Move to London as Growth Continues OBN, the membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and...
BioTrinity 2013 the Most Successful Yet: Move to London as Growth Continues OBN, the membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and...
Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the official program of TAT: Target...
Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the official program of TAT: Target...
Medigus Ltd. (TASE:MDGS), a leading medical device company dedicated to the development of innovative endoscopic procedures and technologies, will be presenting the successful three year follow-up data of the SRS™ pivotal...
Medigus Ltd. (TASE:MDGS), a leading medical device company dedicated to the development of innovative endoscopic procedures and technologies, will be presenting the successful three year follow-up data of the SRS™ pivotal...
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard™ Coronary Embolic Protection Stent (EPS) from...
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard™ Coronary Embolic Protection Stent (EPS) from...
regulated information -- UCB and IBM (NYSE:IBM) today announced the completion of the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care...
regulated information -- UCB and IBM (NYSE:IBM) today announced the completion of the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care...
HealthSparq, a trusted provider of healthcare transparency solutions to many of the nation's largest regional health plans, will debut a new benchmark study at the America's Health Insurance Plans (AHIP) Institute...
HealthSparq, a trusted provider of healthcare transparency solutions to many of the nation's largest regional health plans, will debut a new benchmark study at the America's Health Insurance Plans (AHIP) Institute...
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the publication in the journal Analytical Chemistry of a study by a team of scientists led by Dr. Bruce Kristal, Associate Professor of...
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the publication in the journal Analytical Chemistry of a study by a team of scientists led by Dr. Bruce Kristal, Associate Professor of...
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the...
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the...
Bayer signed an agreement Thursday to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines....
Bayer signed an agreement Thursday to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines....
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard™ Coronary Embolic Protection Stent (EPS) from...
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard™ Coronary Embolic Protection Stent (EPS) from...
Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company...
Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company...
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma") is pleased to provide the following update from President & CEO, Mr. Jeffrey Bacha:
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma") is pleased to provide the following update from President & CEO, Mr. Jeffrey Bacha:
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, released its first quarter ended March 31, 2013 financial results. The company indicated it will host a conference call at a later date to...
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, released its first quarter ended March 31, 2013 financial results. The company indicated it will host a conference call at a later date to...
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax®-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax®-L for brain...
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax®-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax®-L for brain...
TNI BioTech, Inc., (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders...
TNI BioTech, Inc., (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders...
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense...
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense...
Scientists at the Center for Learning and Memory, Tsinghua University, Beijing, and the California-based biopharmaceutical company Magceutics, Inc. (www.magceutics.com) have demonstrated a novel therapy for reversing memory...
Scientists at the Center for Learning and Memory, Tsinghua University, Beijing, and the California-based biopharmaceutical company Magceutics, Inc. (www.magceutics.com) have demonstrated a novel therapy for reversing memory...
Ambit Biosciences Corporation today announced the pricing of its initial public offering of 8,125,000 shares of its common stock at $8.00 per share. Ambit has granted the underwriters a 30-day option to purchase up to an...
Ambit Biosciences Corporation today announced the pricing of its initial public offering of 8,125,000 shares of its common stock at $8.00 per share. Ambit has granted the underwriters a 30-day option to purchase up to an...
The registration deadline has been extended until May 22 for the Association of Bioscience Financial Officers (ABFO) 2013 National Conference, the premier conference for bioscience financial officers. The conference will be...
The registration deadline has been extended until May 22 for the Association of Bioscience Financial Officers (ABFO) 2013 National Conference, the premier conference for bioscience financial officers. The conference will be...
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding...
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding...
Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced on May 13, 2013 that it has...
Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced on May 13, 2013 that it has...
Reportlinker.com announces that a new market research report is available in its catalogue:
Reportlinker.com announces that a new market research report is available in its catalogue:
Reportlinker.com announces that a new market research report is available in its catalogue:
Reportlinker.com announces that a new market research report is available in its catalogue:
Reportlinker.com announces that a new market research report is available in its catalogue:
Reportlinker.com announces that a new market research report is available in its catalogue:
RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody...
RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody...
The consultancy Frost & Sullivan presented its Customer Value Enhancement Award on Tuesday to Germany's largest biometrics manufacturer, DERMALOG Identification Systems, for its exceptional biometric border control...
The consultancy Frost & Sullivan presented its Customer Value Enhancement Award on Tuesday to Germany's largest biometrics manufacturer, DERMALOG Identification Systems, for its exceptional biometric border control...
Fred Hutchinson Cancer Research Center, one of the nation's top cancer research and prevention centers and pioneer of bone marrow and stem cell transplantation, today called on Congress to support restoring full funding...
Fred Hutchinson Cancer Research Center, one of the nation's top cancer research and prevention centers and pioneer of bone marrow and stem cell transplantation, today called on Congress to support restoring full funding...
AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual...
AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual...
Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug...
Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug...
Effective July 1, CCS Medical, a leading provider of home delivery medical equipment and supplies, will be one of only 18 Medicare mail order suppliers providing diabetic testing supplies nationwide.
Effective July 1, CCS Medical, a leading provider of home delivery medical equipment and supplies, will be one of only 18 Medicare mail order suppliers providing diabetic testing supplies nationwide.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for...
Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer...
Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer...
Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational...
Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational...
Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4...
Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4...
Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data in the latest issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0061551) on a new drug target for...
Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data in the latest issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0061551) on a new drug target for...
Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced financial results for the quarter ended March 31, 2013.
Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company, today announced financial results for the quarter ended March 31, 2013.
Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the first quarter ended March 31, 2013.
Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the first quarter ended March 31, 2013.
XBiotech, a privately held biotechnology company, announced today its recent findings for Non-Small Cell Lung Cancer (NSCLC). Sixteen advanced NSCLC patients were treated at MD Anderson Cancer Center with the Company's...
XBiotech, a privately held biotechnology company, announced today its recent findings for Non-Small Cell Lung Cancer (NSCLC). Sixteen advanced NSCLC patients were treated at MD Anderson Cancer Center with the Company's...
A team of international researchers from the J. Craig Venter Institute (JCVI), Synthetic Genomics Inc. (SGI), Novartis Vaccines and Diagnostics, the Biomedical Advanced Research and Development Authority (BARDA, US...
A team of international researchers from the J. Craig Venter Institute (JCVI), Synthetic Genomics Inc. (SGI), Novartis Vaccines and Diagnostics, the Biomedical Advanced Research and Development Authority (BARDA, US...
Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo® (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate...
Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo® (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate...
Edgemont Capital Partners ("Edgemont"), a specialty investment bank focused on the merger and acquisition advisory needs of healthcare companies, has acted as exclusive financial advisor to Vince and Associates Clinical...
Edgemont Capital Partners ("Edgemont"), a specialty investment bank focused on the merger and acquisition advisory needs of healthcare companies, has acted as exclusive financial advisor to Vince and Associates Clinical...
The National Venture Capital Association (NVCA) today announced the election of Arthur M. Pappas, managing partner of Pappas Ventures, to its board of directors. He will serve a four-year term. The appointment was made...
The National Venture Capital Association (NVCA) today announced the election of Arthur M. Pappas, managing partner of Pappas Ventures, to its board of directors. He will serve a four-year term. The appointment was made...
ACell, Inc., a leading developer of next-generation regenerative medicine products, announced today that its MatriStem medical devices demonstrate the highest constructive remodeling response in a recent study comparing 14...
ACell, Inc., a leading developer of next-generation regenerative medicine products, announced today that its MatriStem medical devices demonstrate the highest constructive remodeling response in a recent study comparing 14...
Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering to sell an aggregate of 9.5 million shares of its common stock under Discovery Labs' previously...
Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering to sell an aggregate of 9.5 million shares of its common stock under Discovery Labs' previously...
Pharma IQ is pleased to announce the release of a brand new infographic summary of the results from an industry survey conducted earlier this year. Building an intelligent lab informatics system is fast becoming an...
Pharma IQ is pleased to announce the release of a brand new infographic summary of the results from an industry survey conducted earlier this year. Building an intelligent lab informatics system is fast becoming an...
Today Gradalis, Inc. announced that FANG™, the company's tumor-based personalized cancer vaccine, elicits an immune response and delays time to recurrence in advanced stage ovarian cancer patients by more than one year...
Today Gradalis, Inc. announced that FANG™, the company's tumor-based personalized cancer vaccine, elicits an immune response and delays time to recurrence in advanced stage ovarian cancer patients by more than one year...
The increasingly central role of corporate venture, the adaptation of the traditional venture model to the economic times, and the return of the bull market were all raised as themes at this year's BioTrinity conference....
The increasingly central role of corporate venture, the adaptation of the traditional venture model to the economic times, and the return of the bull market were all raised as themes at this year's BioTrinity conference....
Simbionix, a world leader in medical simulation, and the American College of Chest Physicians (ACCP), the leader in advanced simulation education, will collaborate to promote bronchoscopy education. This partnership...
Simbionix, a world leader in medical simulation, and the American College of Chest Physicians (ACCP), the leader in advanced simulation education, will collaborate to promote bronchoscopy education. This partnership...
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical and pharmaceutical, today announced that the Company's Phytofare™...
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical and pharmaceutical, today announced that the Company's Phytofare™...
Researchers from academia throughout Europe are invited to participate In a newly created award, pRED`s Discovery Oncology unit of Roche (SIX: RO, ROG; OTCQX: RHHBY) in Penzberg, Germany invites European researchers to...
Researchers from academia throughout Europe are invited to participate In a newly created award, pRED`s Discovery Oncology unit of Roche (SIX: RO, ROG; OTCQX: RHHBY) in Penzberg, Germany invites European researchers to...
Program's second cohort includes eQOL, E-Twenty Development, Root2Crown, Treata Smart Solutions and TrendMD
Program's second cohort includes eQOL, E-Twenty Development, Root2Crown, Treata Smart Solutions and TrendMD
ILC Dover, the designer and manufacturer of NASA's space suits and a wide range of engineered film and fabric products, announced today it has received certification for its ISO Class 7 Clean Room. Testing of the...
ILC Dover, the designer and manufacturer of NASA's space suits and a wide range of engineered film and fabric products, announced today it has received certification for its ISO Class 7 Clean Room. Testing of the...
BASF (BAS.DE) and Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI) announced today that the two Companies have entered into a non-exclusive worldwide research and license agreement.
BASF (BAS.DE) and Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI) announced today that the two Companies have entered into a non-exclusive worldwide research and license agreement.
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013.
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013.
Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has closed a $20 million private placement of shares of its Series...
Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has closed a $20 million private placement of shares of its Series...
Venture capital (VC) funding in the Life Sciences sector, which includes the Biotechnology and Medical Device industries, dropped in volume and value during the first quarter of 2013 according to a new PwC US report,...
Venture capital (VC) funding in the Life Sciences sector, which includes the Biotechnology and Medical Device industries, dropped in volume and value during the first quarter of 2013 according to a new PwC US report,...
ArcDia Ltd (http://www.arcdia.com). ArcDia International Ltd has released results from a clinical study comparing its rapid mariPOC® test product to the standard bacterial culture in detection of Group A streptococcal...
ArcDia Ltd (http://www.arcdia.com). ArcDia International Ltd has released results from a clinical study comparing its rapid mariPOC® test product to the standard bacterial culture in detection of Group A streptococcal...
Sigma-Tau Pharmaceuticals, Inc. announced today that the Company was recognized last evening as a rare disease pioneer at the 30th anniversary celebration of The National Organization for Rare Disorders (NORD). During the...
Sigma-Tau Pharmaceuticals, Inc. announced today that the Company was recognized last evening as a rare disease pioneer at the 30th anniversary celebration of The National Organization for Rare Disorders (NORD). During the...
QUÉBEC CITY, May 15, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the Company's Senior Vice President and CFO, Dennis Turpin CPA CA, will be presenting a...
QUÉBEC CITY, May 15, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the Company's Senior Vice President and CFO, Dennis Turpin CPA CA, will be presenting a...
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet...
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet...
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2013. Net sales of KRYSTEXXA® (pegloticase) were $4.4 million for the first quarter of 2013, a 6% decrease...
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2013. Net sales of KRYSTEXXA® (pegloticase) were $4.4 million for the first quarter of 2013, a 6% decrease...
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and...
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and...
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May...
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May...
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the following upcoming investor conferences.
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the following upcoming investor conferences.
Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical...
Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical...
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its microRNA therapeutic pipeline under the...
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its microRNA therapeutic pipeline under the...
KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a primary clinical focus on respiratory...
KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a primary clinical focus on respiratory...
Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that the Board of Directors has unanimously elected Scott Brooks as the next Chief Executive Officer (CEO), and member...
Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that the Board of Directors has unanimously elected Scott Brooks as the next Chief Executive Officer (CEO), and member...
Reportlinker.com announces that a new market research report is available in its catalogue:
Reportlinker.com announces that a new market research report is available in its catalogue:
Reportlinker.com announces that a new market research report is available in its catalogue:
Reportlinker.com announces that a new market research report is available in its catalogue:
Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9, 2013. The shares were sold at a price of $4.14 per share,...
Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9, 2013. The shares were sold at a price of $4.14 per share,...
Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced results for its first quarter ended March 31st, 2013.
Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced results for its first quarter ended March 31st, 2013.
The J. Craig Venter Institute (JCVI) announced today the launch of their mobile genomics laboratory program in the San Diego, California area. The DiscoverGenomics! Mobile Laboratory is a self-sufficient laboratory on...
The J. Craig Venter Institute (JCVI) announced today the launch of their mobile genomics laboratory program in the San Diego, California area. The DiscoverGenomics! Mobile Laboratory is a self-sufficient laboratory on...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European hematological oncologists indicate that overall survival is the...
Callidus Biopharma, Inc., a development-stage biotechnology company focused on creating breakthrough biologic drugs for a range of orphan diseases, announced today that it has closed on $4.6 million in Series A financing led...
Callidus Biopharma, Inc., a development-stage biotechnology company focused on creating breakthrough biologic drugs for a range of orphan diseases, announced today that it has closed on $4.6 million in Series A financing led...
GenoVive is forming worldwide partnerships and is engaged in discussions with several countries in Europe and other continents to bring its "Weight Loss Designed by Science" program internationally. Vic Castellon, PhamD....
GenoVive is forming worldwide partnerships and is engaged in discussions with several countries in Europe and other continents to bring its "Weight Loss Designed by Science" program internationally. Vic Castellon, PhamD....
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S....
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S....
Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as...
Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as...
